Istradefylline

Drug Profile

Istradefylline

Alternative Names: KW-6002; Nouriast

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kyowa Hakko
  • Developer Kyowa Hakko; Kyowa Hakko Kirin
  • Class Antidepressants; Antiparkinsonians; Neuroprotectants; Purines; Small molecules
  • Mechanism of Action Adenosine A2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Parkinson's disease
  • No development reported Drug abuse
  • Discontinued Major depressive disorder; Restless legs syndrome

Most Recent Events

  • 28 Feb 2018 No recent reports of development identified for phase-I development in Drug-abuse in USA (PO, Tablet)
  • 20 Dec 2017 Kyowa Hakko Kirin Pharma completes a long-term phase III trial for Parkinson's disease in USA, Canada, Czech Republic, Germany, Israel, Italy, Poland, Serbia (NCT02610231)
  • 13 Dec 2016 Top-line efficacy and adverse events data from a phase III trial in parkinson's disease released by Kyowa Hakko Kirin
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top